These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831 [TBL] [Abstract][Full Text] [Related]
9. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel. Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598 [TBL] [Abstract][Full Text] [Related]
10. Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience. Grenader T; Plotkin Y; Gips M; Cherny N; Gabizon A Oncol Rep; 2014 Jan; 31(1):428-34. PubMed ID: 24247716 [TBL] [Abstract][Full Text] [Related]
11. Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians. Sureka SK; Maheshwari R; Agnihotri S; Mitash N; Ahmad S; Mandhani A Indian J Med Res; 2016 May; 143(Supplement):S68-S73. PubMed ID: 27748280 [TBL] [Abstract][Full Text] [Related]
12. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ; Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048 [TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337 [TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid. Saad F; Segal S; Eastham J Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317 [TBL] [Abstract][Full Text] [Related]
15. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database. Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853 [TBL] [Abstract][Full Text] [Related]
18. [Efficacy and Prognostic Factors of Estracyt ® in Patients with Castration-Resistant Prostate Cancer (CRPC) : From the Data Analysis of Estracyt ® Special Drug Use Investigation]. Murachi K; Kumagai T; Masuda T; Nakanishi T; Tanaka S; Tajima K; Takebe Y; Oda T Hinyokika Kiyo; 2016 Jun; 62(6):295-306. PubMed ID: 27452492 [TBL] [Abstract][Full Text] [Related]
19. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases. Yashi M; Nishihara D; Mizuno T; Yuki H; Masuda A; Kambara T; Betsunoh H; Abe H; Fukabori Y; Muraishi O; Kamai T Clin Genitourin Cancer; 2014 Oct; 12(5):e197-203. PubMed ID: 24674784 [TBL] [Abstract][Full Text] [Related]